Substance / Medication

Sacituzumab govitecan

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta-Analysis.
Dello Russo Cinzia, Asiimwe Innocent Gerald, Pushpakom Sudeep et al. · Clin Pharmacol Ther · 2026
PMID: 40936312Meta-AnalysisFull text (PMC)
Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis.
Dacoregio Maria Inez, Michelon Isabella, Ernesto do Rego Castro Caio et al. · Breast · 2025
PMID: 39616817Meta-AnalysisFull text (PMC)
Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis.
Zhang Yaping, Chen Jian, Wang Xiaoyan et al. · Front Oncol · 2025
PMID: 40626021Meta-AnalysisFull text (PMC)
A meta-analysis and systematic review of the first Trop-2-targeting antibody-drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer.
Wang Jue, Lin Shengyou, Zhang Jialin et al. · Eur J Clin Pharmacol · 2025
PMID: 40624355Meta-Analysis
Sacituzumab govitecan as a therapeutic breakthrough in the treatment of triple-negative breast cancer: a systematic review of clinical trials.
Piekarz Julia, Picheta Natalia, Pobideł Jakub et al. · Front Immunol · 2025
PMID: 41601628Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Sacituzumab govitecan (substance)
SNOMED CT
871701001
UMLS CUI
C4086837

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.